What's On

VIC Stem Cell Network - September 2015 Seminar

04:00 PM - Tuesday 01 September, 2015
Join us to hear Dr Rebecca Lim from Monash University's Hudson Institute of Medical Research discuss her journey as a scientist taking research from bench to bedside.

VENUE: Level 5, Seminar Room, Melbourne Brain Centre, The University of Melbourne
WHEN: Tuesday 1 September @4PM
TITLE: Bench-to-bedside: A scientist's journey



Abstract:  Gestational tissues are a well-recognised source of stem cells and stem-like cells. The regenerative properties of the human amniotic membrane has been recognised in medical practice for decades. My research has focused on characterising and understanding the regenerative potential of amnion epithelial cells, which we have now taken to a Phase I safety trial at Monash Newborn. This talk will cover some of our pivotal research findings and describe how we have made this move from basic research to clinical trials. In particular, I will cover our challenges in moving into GMP production, approval for human ethics, working with a clinical team and funding these early phase studies.

Bio: Dr Rebecca Lim is a research group leader at The Ritchie Centre, Hudson Institute of Medical Research. She leads a team focused on uncovering the regenerative potential of amnion derived stem-like cells while concurrently pursuing clinical translation of her findings. In recent years, her team has uncovered key immunological events that are critical to the success of amnion cell mediated lung and liver repair in the settings of acute and chronic disease. Most recently she has shown that amnion cells trigger endogenous repair processes by activating the adult stem cell niche and recruiting distal progenitor sites to the area of injury. Research from her lab is focused at understanding fundamental mechanisms of action in order to design informative clinical trials and best exploit the use of amnion cells in regenerative medicine. She is the chief investigator on a Phase I trial assessing the safety of intravenously delivered amnion cells in babies with established bronchopulmonary dysplasia.